Long-term low-dose IL-2 enhances immune function in common variable immunodeficiency
Long-term low-dose IL-2 enhances immune function in common variable immunodeficiency
复制标题
DOI：
10.1006/clim.2001.5052
复制
发表时间：
2001-08-01
影响因子：
8.6
通讯作者：
Zhuo, Z
中科院分区：
文献类型：
--
作者：
Cunningham-Rundles, C;Bodian, C;Zhuo, Z
常见变异型免疫缺陷病（CVID）是一种以低丙种球蛋白血症和缺乏抗体产生为特征的原发性免疫缺陷病。已经描述了许多T细胞缺陷，包括降低的基因表达和IL-2的产生。由于一些T细胞缺陷可以解释为缺乏IL-2，我们一直在研究体内IL-2治疗的效果。在此，将IL-2的长效形式PEG-IL-2给予15名随机选择的CVID受试者12-18个月，与作为对照的39名CVID受试者进行比较。治疗6 ~ 12个月后，T细胞对促分裂原和IL-2的增殖反应显著增强;对破伤风和念珠菌抗原的增殖反应增加了50倍。用新抗原噬菌体phiX 174免疫的8名受试者中有4名在治疗后显示出增加的抗体应答。治疗受试者记录的支气管炎、腹泻和关节疼痛天数减少，但总体上无统计学显著性。这些数据表明，IL-2可能作为一种辅助治疗在一些受试者与CVID，增强T细胞功能和逆转T细胞无反应性在大多数。(C)北京：科学出版社.
Common variable immunodeficiency (CVID) is a primary immunodeficiency disease characterized by hypogammaglobulinemia and lack of antibody production. Numerous T cell defects have been described, including reduced gene expression and production of IL-2. Since some of the T cell defects could be explained by lack of IL-2, we have been investigating the effects of in vivo IL-2 treatment. Here, a long-acting form of IL-2, PEG-IL-2, was given for 12-18 months to 15 randomly chosen CVID subjects, in comparison to 39 CVID subjects who served as controls. After 6 to 12 months of treatment, T cell proliferative responses to mitogens and to IL-2 were significantly enhanced; proliferative responses to tetanus and candida antigens increased up to 50-fold. Four of eight subjects immunized with the neoantigen bacteriophage phiX 174 displayed increased antibody responses after treatment. Treated subjects recorded reduced, but not overall statistically significant, days of bronchitis, diarrhea, and joint pain. These data indicate that IL-2 might serve as an adjuvant to therapy in some subjects with CVID, enhancing T cell functions and reversing T cell anergy in most. (C) 2001 Academic Press.